SARS-CoV-2 Neutralizing Monoclonal Antibodies for the Treatment of COVID-19 in Kidney Transplant Recipients.

Aileen X Wang Stephan BusqueJamie KuoUpinder Singh Katharina Röeltgen Benjamin A Pinsky Glenn M ChertowJohn D ScandlingColin R Lenihan

Published in: Kidney360 (2021)

Bamlanivimab and casirivimab-imdevimab combined with immunosuppression reduction were well tolerated and associated with favorable clinical outcomes in kidney transplant recipients diagnosed with mild to moderate COVID-19.

Keyphrases

sars cov
coronavirus disease
respiratory syndrome coronavirus
smoking cessation